Cargando…

Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer

CD97 is a member of the epidermal growth factor-seven transmembrane family. It affects tumor aggressiveness by binding its cellular ligand CD55 and exhibits adhesive properties. Previous studies have shown that CD97 and CD55 are involved in the dedifferentiation, migration, invasiveness and metastas...

Descripción completa

Detalles Bibliográficos
Autores principales: HE, ZHENG, WU, HUI, JIAO, YANLI, ZHENG, JUN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301556/
https://www.ncbi.nlm.nih.gov/pubmed/25624904
http://dx.doi.org/10.3892/ol.2014.2751
_version_ 1782353667062497280
author HE, ZHENG
WU, HUI
JIAO, YANLI
ZHENG, JUN
author_facet HE, ZHENG
WU, HUI
JIAO, YANLI
ZHENG, JUN
author_sort HE, ZHENG
collection PubMed
description CD97 is a member of the epidermal growth factor-seven transmembrane family. It affects tumor aggressiveness by binding its cellular ligand CD55 and exhibits adhesive properties. Previous studies have shown that CD97 and CD55 are involved in the dedifferentiation, migration, invasiveness and metastasis of tumors. However, little is known regarding the roles of CD97 and CD55 in pancreatic cancer. In this study, immunohistochemistry was used to analyze CD97 and CD55 protein expression in samples obtained from 37 pancreatic cancer patients. CD97 and CD55 were absent or only weakly expressed in the normal pancreatic tissues but strongly expressed in pancreatic cancer tissues (P<0.05), particularly in tissues with lymph node involvement, metastasis or vascular invasion (P<0.05). Notably, CD97 and CD55 were expressed consistently in pancreatic cancer tissues (r(2)=0.5422; P<0.05). In addition, CD97 and CD55 expression levels were found to significantly correlate with tumor aggressiveness (P<0.01). Multivariate analyses revealed that CD97 and CD55 expression levels were closely associated with prognosis (P<0.05). Taken together, these results indicated that CD97 and its ligand CD55 are upregulated in pancreatic cancers and are closely associated with lymph node involvement, metastasis and vascular invasion. Thus, analysis of both CD97 and CD55 expression may present potential prognostic value for pancreatic cancer.
format Online
Article
Text
id pubmed-4301556
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-43015562015-01-26 Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer HE, ZHENG WU, HUI JIAO, YANLI ZHENG, JUN Oncol Lett Articles CD97 is a member of the epidermal growth factor-seven transmembrane family. It affects tumor aggressiveness by binding its cellular ligand CD55 and exhibits adhesive properties. Previous studies have shown that CD97 and CD55 are involved in the dedifferentiation, migration, invasiveness and metastasis of tumors. However, little is known regarding the roles of CD97 and CD55 in pancreatic cancer. In this study, immunohistochemistry was used to analyze CD97 and CD55 protein expression in samples obtained from 37 pancreatic cancer patients. CD97 and CD55 were absent or only weakly expressed in the normal pancreatic tissues but strongly expressed in pancreatic cancer tissues (P<0.05), particularly in tissues with lymph node involvement, metastasis or vascular invasion (P<0.05). Notably, CD97 and CD55 were expressed consistently in pancreatic cancer tissues (r(2)=0.5422; P<0.05). In addition, CD97 and CD55 expression levels were found to significantly correlate with tumor aggressiveness (P<0.01). Multivariate analyses revealed that CD97 and CD55 expression levels were closely associated with prognosis (P<0.05). Taken together, these results indicated that CD97 and its ligand CD55 are upregulated in pancreatic cancers and are closely associated with lymph node involvement, metastasis and vascular invasion. Thus, analysis of both CD97 and CD55 expression may present potential prognostic value for pancreatic cancer. D.A. Spandidos 2015-02 2014-12-01 /pmc/articles/PMC4301556/ /pubmed/25624904 http://dx.doi.org/10.3892/ol.2014.2751 Text en Copyright © 2015, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
HE, ZHENG
WU, HUI
JIAO, YANLI
ZHENG, JUN
Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer
title Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer
title_full Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer
title_fullStr Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer
title_full_unstemmed Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer
title_short Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer
title_sort expression and prognostic value of cd97 and its ligand cd55 in pancreatic cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301556/
https://www.ncbi.nlm.nih.gov/pubmed/25624904
http://dx.doi.org/10.3892/ol.2014.2751
work_keys_str_mv AT hezheng expressionandprognosticvalueofcd97anditsligandcd55inpancreaticcancer
AT wuhui expressionandprognosticvalueofcd97anditsligandcd55inpancreaticcancer
AT jiaoyanli expressionandprognosticvalueofcd97anditsligandcd55inpancreaticcancer
AT zhengjun expressionandprognosticvalueofcd97anditsligandcd55inpancreaticcancer